Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial.
Kedhi E, Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van' T Hof AW, Lee SW, Roolvink V, Ligtenberg E, Postma S, Kolkman EJ, Brouwer MA, Dudek D, De Luca G. Kedhi E, et al. Among authors: benit e. Atherosclerosis. 2021 Mar;321:39-44. doi: 10.1016/j.atherosclerosis.2021.02.006. Epub 2021 Feb 16. Atherosclerosis. 2021. PMID: 33639478 Clinical Trial.
How many times can a heart be broken?
Mulleners T, Dilling-Boer D, Benit E. Mulleners T, et al. Among authors: benit e. Acta Cardiol. 2009 Jun;64(3):435-8. doi: 10.2143/AC.64.3.2038037. Acta Cardiol. 2009. PMID: 19593962
Final results of the HEALING IIB trial to evaluate a bio-engineered CD34 antibody coated stent (Genous™Stent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients.
den Dekker WK, Houtgraaf JH, Onuma Y, Benit E, de Winter RJ, Wijns W, Grisold M, Verheye S, Silber S, Teiger E, Rowland SM, Ligtenberg E, Hill J, Wiemer M, den Heijer P, Rensing BJ, Channon KM, Serruys PW, Duckers HJ. den Dekker WK, et al. Among authors: benit e. Atherosclerosis. 2011 Nov;219(1):245-52. doi: 10.1016/j.atherosclerosis.2011.06.032. Epub 2011 Jun 25. Atherosclerosis. 2011. PMID: 21763653 Free article. Clinical Trial.
Differences in cardiovascular risk factors and clinical outcomes between Western European and Southeast Asian patients treated with the Genous Bio-engineered R stent: an e-HEALING worldwide registry substudy.
Klomp M, Damman P, Beijk MA, Tan KH, Balian V, de Luca G, Tijssen JG, Silber S, de Winter RJ; e-HEALING investigators. Klomp M, et al. Coron Artery Dis. 2012 Jun;23(4):271-7. doi: 10.1097/MCA.0b013e328351aaed. Coron Artery Dis. 2012. PMID: 22473083
Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: the MEDCOR Trial.
Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W. Barbato E, et al. Among authors: benit e. J Cardiovasc Transl Res. 2014 Mar;7(2):226-31. doi: 10.1007/s12265-013-9513-9. Epub 2013 Oct 19. J Cardiovasc Transl Res. 2014. PMID: 24142804 Clinical Trial.
Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial.
Barbato E, Herman A, Benit E, Janssens L, Lalmand J, Hoffer E, Chenu P, Guédès A, Missault L, Pirenne B, Cardinal F, Vercauteren S, Wijns W. Barbato E, et al. Among authors: benit e. Atherosclerosis. 2015 Jun;240(2):351-4. doi: 10.1016/j.atherosclerosis.2015.03.045. Epub 2015 Apr 7. Atherosclerosis. 2015. PMID: 25875387 Clinical Trial.
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, McFadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S; GLOBAL LEADERS Investigators. Vranckx P, et al. Among authors: benit e. Lancet. 2018 Sep 15;392(10151):940-949. doi: 10.1016/S0140-6736(18)31858-0. Epub 2018 Aug 27. Lancet. 2018. PMID: 30166073 Clinical Trial.
102 results